NUVL Nuvalent, Inc. Class A Common Stock Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
01:11
Jun 09
seedy19tron Biotech trader, L/S
Reports an M&A deal between NUVL and GSK valued >$9B, a fundamental event; speaker reacts positively but no personal position.
NUVL
LOW
01:06
Jun 09
FirstSquawk Newswire (@FirstSquawk)
The Financial Times reports that a deal between GSK and Nuvalent is expected to be finalized as early as this week.
NUVL
01:05
Jun 09
FirstSquawk Newswire (@FirstSquawk)
GSK is in talks to acquire cancer-focused biotech Nuvalent in a deal valued at more than nine billion dollars according to the Financial Times.
NUVL

About NUVL Analyst Coverage

Buzzberg tracks NUVL (Nuvalent, Inc. Class A Common Stock) across 2 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked.